Biogen Inc (BIIB) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Biogen Inc (BIIB) - Pharmaceuticals & Healthcare - Deals and Alliances Profile


  • Products Id :- GDPH1307D
  • |
  • Pages: 160
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Summary

Biogen Inc (Biogen) is a global biopharmaceutical company that discovers, develops and delivers drugs for the treatment of neurological and neurodegenerative diseases worldwide. The company's marketed products include Avonex (interferon beta-1a), Tysabri (natalizumab), Tecfidera (dimethyl fumarate), Zinbryta (daclizumab), Fampyra (prolonged-release fampridine tablets) and Plegridy (peginterferon beta-1a) for the treatment of multiple sclerosis (MS); Spinraza (nusinersen) for spinal muscular atrophy (SMA); and Fumaderm (fumaric acid esters) for severe plaque psoriasis. The company also offers biosimilars through its joint venture, Samsung Bioepis. It has several products candidates targeting various indications such as MS, Parkinson's disease, Alzheimer's disease and idiopathic pulmonary fibrosis, stroke, among others. The company sells its products through direct sales forces, marketing groups and distributors in the Americas, Europe, Asia and other territories. Biogen is headquartered in Cambridge, Massachusetts, the US.

Biogen Inc (BIIB)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 3

List of Tables 6

List of Figures 7

Biogen Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 8

Biogen Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 9

Biogen Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 10

Biogen Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 11

Biogen Inc, Medical Devices Deals, 2012 to YTD 2018 13

Biogen Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 14

Biogen Inc, Pharmaceuticals & Healthcare, Deal Details 19

Asset Purchase 19

Biogen Acquires ALG-801 and ALG-802 from AliveGen 19

Biogen to Acquire TMS-007 Asset from TMS 20

Biogen Acquires CIAS Asset from Pfizer for up to USD590 Million 21

Biogen Acquires Rights to KPT-350 from Karyopharm Therapeutics 22

Biogen Acquires CIRARA from Remedy Pharma 23

Biogen Idec Completes Acquisition Of Tysabri From Elan 24

Venture Financing 26

Solid Biosciences Raises USD50 Million in Series C Financing 26

Yumanity Therapeutics Raises USD45 Million in Series A Financing Round 28

Solid GT Raises USD42.5 Million in Series B Financing Round 30

True North Therapeutics Raises USD22 Million in Series A Venture Financing 31

Ataxion Raises USD 17 Million In Series A Financing 32

iPierian Raises USD 30 Million In Series A Venture Financing 33

Knopp Biosciences Raises USD 15 Million In First Tranche Of Venture Financing 35

Probiodrug Secures USD 19.5 Million In Series C Financing 36

Partnerships 38

Biogen Exercises Option Agreement with Neurimmune 38

Biogen and Ionis Pharma Enter into Agreement 39

Biogen and Ionis Pharma Enter into Agreement 40

Eisai Enters into Co-Promotion Agreement with Biogen 41

Biogen Enters into Partnership with Genomics 42

Ewopharma Enters into Distribution Agreement with Biogen 43

Siemens Healthcare Enters into Co-Development Agreement with Biogen 44

Amyris Enters into Agreement with Biogen 45

Biogen Enters into Co-Development Agreement with University of Pennsylvania 46

AC Immune Enters into Partnership with Biogen 47

Rodin Therapeutics Enters into R&D Agreement with Biogen 48

Arsia Therapeutics Enters into Research Agreement with Biogen 49

BioMotiv Expands its Agreement with Biogen 50

Renovo Neural Partners with Biogen 51

Biogen Enters into Agreement with Parkinson's Institute and Clinical Center 52

Biogen's Partner Swedish Orphan Biovitrum To Exercise Its Option for Alprolix 53

Intec Pharma Enters into Research Agreement with Biogen MA 54

Biogen Idec, Fondazione Telethon and Ospedale San Raffaele Enter into Agreement to Develop Gene Therapies for Hemophilia 56

Biogen Idec Enters into Research Agreement with Columbia University Medical Center 57

Swedish Orphan Biovitrum Exercises Option Agreement with Biogen Idec for Elocta 58

Biogen Idec Expands Co-Development Agreement with Swedish Orphan Biovitrum 59

Array BioPharma Enters into Drug Discovery Agreement with Biogen Idec 60

Evotec Enters Into Agreement With Panion For Developing Chronic Pain Treatments 61

White Head Institute And Biogen Idec Enter Into Reasearch Agreement 62

Eisai Expands Co-Development Agreement with Biogen 63

Biogen Idec Enters Into Agreement With UCB To Commercialize Multiple Sclerosis And Hemophilia Therapies 65

Biogen Idec Enters Into Co-Marketing Agreement With Samsung Bioepis To Commercialize Anti-TNF Biosimilar Product Candidates 66

Amicus Therapeutics Enters Into Co-Development Agreement With Biogen Idec 67

Biogen Idec And Isis Pharma Enter Into R&D Agreement To Develop Treatments For Neurological Disorders 68

Biogen Idec Enters Into Agreement With Isis Pharma To Develop Antisense Drugs For Neurological Disorders 69

Biogen Idec Enters Into Agreement With Isis Pharma To Develop Antisense Drug For Myotonic Dystrophy 70

Samsung Forms Joint Venture With Biogen Idec 72

Biogen Idec Amends Co-Development Agreement With Swedish Orphan Biovitrum For rFVIIIFc And rFIXFc Hemophilia Programs 73

Biogen Idec Enters Into Co-Development Agreement With Isis Pharma 74

Licensing Agreements 75

Biogen Enters into Licensing Agreement with Alkermes 75

Biogen Enters into Licensing Agreement with Bristol-Myers Squibb 76

Biogen Enters into Licensing Agreement with Forward Pharma 77

Biogen Exercises Option for Licensing Agreement with Amunix Operating for Factor IX, XTEN technology 79

Biogen Exercises Option for Licensing Agreement with Ionis Pharma 80

Biogen Enters into Licensing Agreement with RegenxBio 81

Biogen Enters into Licensing Agreement with Applied Genetic Technologies 82

bluebird bio Enters into Licensing Agreement with Biogen 83

Biogen Idec Exercises Option For Licensing Agreement With Amunix Operating For XTENylated Factor VIII 84

Biogen Idec Enters into Licensing Agreement with Sangamo BioSciences for Hemoglobinopathies Therapeutics 85

Sunesis Pharma Enters Into Licensing Agreement With Biogen Idec 86

MAKScientific Enters Into Option For Licensing Agreement With Biogen Idec 87

Biogen Idec Enters Into Licensing Agreement With Myelin Repair Foundation 88

Equity Offering 89

Bioverativ Spin Off from Biogen 89

Rodin Therapeutics to Raise USD17.3 Million in Private Placement of Preferred Stock 90

Applied Genetic Tech Raises USD30 Million in Private Placement of Shares 91

Debt Offering 93

Biogen Raises USD1.5 Billion in Public Offering of 2.9% Notes Due 2020 93

Biogen Raises USD1.75 Billion in Public Offering of 5.2% Notes Due 2045 95

Biogen Raises USD1.75 Billion in Public Offering of 4.05% Notes Due 2025 97

Biogen Raises USD1 Billion in Public Offering of 3.625% Notes Due 2022 99

Asset Transactions 101

Brammer Bio Acquires Cambridge Site from Biogen 101

Kiniksa Pharma Acquires Certain Assets Relating to KPL-716 from Biogen 102

Royalty Pharma Acquires Additional Stake In Tecfidera, Oral Multiple Sclerosis Drug, For USD 510 Million 104

DRI Capital Acquires Royalty Rights To Benlysta From Biogen Idec 105

Royalty Pharma Acquires BG-12 And Fumaderm From Fumapharm For USD 761 Million 106

Acquisition 107

Biogen to Acquire 44.5% Stake in Samsung Bioepis from Samsung BioLogics for USD700 Million 107

Biogen Idec Acquires Convergence Pharma for up to USD650.1 Million 108

Bristol-Myers Rumored To Acquire Biogen Idec 109

Biogen Idec Completes Acquisition Of Remaining Stake In Stromedix, Provider Of Therapies For Fibrosis 110

Takeda Completes Acquisition Of Intellikine For USD 310 Million 112

Biogen Inc-Key Competitors 114

Biogen Inc-Key Employees 115

Biogen Inc-Locations And Subsidiaries 117

Head Office 117

Other Locations & Subsidiaries 117

Joint Venture 121

Recent Developments 122

Financial Announcements 122

Jul 24, 2018: Biogen Q2 2018 revenues increase 9% tO USD 3.4 122

Jan 25, 2018: Biogen Reports Revenues for Both the Full Year and Fourth Quarter of 2017 125

Oct 24, 2017: Biogen Reports Quarterly Revenues of USD 3.1 Billion 128

Jul 25, 2017: Biogen Reports Record Quarterly Revenues of USD 3.1 Billion, Raises Full Year Revenue Guidance 130

Apr 25, 2017: Biogen Reports First Quarter 2017 Revenues of USD 2.8 Billion 133

Jan 26, 2017: Biogen Reports 2016 Revenues of USD 11.4 Billion 135

Corporate Communications 137

Dec 04, 2017: Biogen Appoints Mark Hernon as SVP, Chief Information Officer 137

Nov 21, 2017: Biogen Appoints Jeff Capello as Executive Vice President and Chief Financial Officer 138

Sep 25, 2017: Biogen Appoints Camille Lee as SVP, Alzheimer's Disease Therapeutic Area 139

Sep 12, 2017: Biogen Appoints Sanjay Jariwala as SVP, Worldwide Medical 140

Jun 20, 2017: Biogen Appoints Ginger Gregory Executive Vice President, Chief Human Resources Officer 141

Jun 14, 2017: Jean-Paul Kress Appointed EVP and President, International and Head of Global Therapeutic Operations 142

Jun 13, 2017: Biogen Announces Management Change 143

Mar 16, 2017: Biogen Appoints Anirvan Ghosh Senior Vice President, Research and Early Development 144

Feb 01, 2017: Biogen Completes Separation of Global Hemophilia Business, Bioverativ 145

Jan 12, 2017: Biogen Spin-off Bioverativ Commences When-Issued Trading of Common Stock 146

Legal and Regulatory 147

Aug 23, 2018: SEC Charges Former Pharma Executive and Others with Insider Trading 147

Sep 05, 2017: Forward Pharma Files Opening Brief in the Appeal of the U.S. Patent Interference to the Federal Circuit 148

May 01, 2017: Forward Pharma Further Aligns Cost Structure with Focus Following Settlement and License Agreement 149

Feb 09, 2017: Forward Pharma Received USD 1.25bn pursuant to Settlement and License Agreement with Biogen 150

Government and Public Interest 151

Jun 18, 2018: Biogen Foundation Selects Grantees to Receive USD 10 Million Investment for STEM Education 151

May 27, 2018: Specialists in multiple sclerosis discuss the real world of patients 152

Product News 153

03/28/2017: Biogen to Present Data on BIIB054 at the 13th International Conference on Alzheimer's and Parkinson's Diseases 153

02/09/2017: Karyopharm and Collaborators Awarded Grant for ALS Drug Development 154

Product Approvals 155

Jan 16, 2017: Remedy Pharmaceuticals CIRARA Granted Orphan Drug Designation For Treatment of Severe Cerebral Edema Caused By Acute Ischemic Stroke 155

Clinical Trials 156

Oct 27, 2017: Alkermes Presents Data Demonstrating Safety and Gastrointestinal Tolerability Profile of ALKS 8700 for the Treatment of Multiple Sclerosis 156

Oct 16, 2017: Alkermes to Present New Clinical Data on ALKS 8700 at MSParis2017, the 7th Joint ECTRIMS-ACTRIMS Meeting 157

Mar 16, 2017: Alkermes Initiates Phase 3 Gastrointestinal Tolerability Study of ALKS 8700 for Treatment of Multiple Sclerosis 158

Feb 19, 2017: BIIB076 Moves into Phase 1 for Alzheimer Disease 159

Appendix 160

Methodology 160

About GlobalData 160

Contact Us 160

Disclaimer 160

List of Figures

Biogen Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Biogen Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Biogen Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Biogen Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Biogen Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 8

Biogen Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 9

Biogen Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 10

Biogen Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 11

Biogen Inc, Medical Devices Deals, 2012 to YTD 2018 13

List of Tables

Biogen Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Biogen Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 8

Biogen Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 9

Biogen Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 10

Biogen Inc, Deals By Therapy Area, 2012 to YTD 2018 11

Biogen Inc, Medical Devices Deals, 2012 to YTD 2018 13

Biogen Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 14

Biogen Acquires ALG-801 and ALG-802 from AliveGen 19

Biogen to Acquire TMS-007 Asset from TMS 20

Biogen Acquires CIAS Asset from Pfizer for up to USD590 Million 21

Biogen Acquires Rights to KPT-350 from Karyopharm Therapeutics 22

Biogen Acquires CIRARA from Remedy Pharma 23

Biogen Idec Completes Acquisition Of Tysabri From Elan 24

Solid Biosciences Raises USD50 Million in Series C Financing 26

Yumanity Therapeutics Raises USD45 Million in Series A Financing Round 28

Solid GT Raises USD42.5 Million in Series B Financing Round 30

True North Therapeutics Raises USD22 Million in Series A Venture Financing 31

Ataxion Raises USD 17 Million In Series A Financing 32

iPierian Raises USD 30 Million In Series A Venture Financing 33

Knopp Biosciences Raises USD 15 Million In First Tranche Of Venture Financing 35

Probiodrug Secures USD 19.5 Million In Series C Financing 36

Biogen Exercises Option Agreement with Neurimmune 38

Biogen and Ionis Pharma Enter into Agreement 39

Biogen and Ionis Pharma Enter into Agreement 40

Eisai Enters into Co-Promotion Agreement with Biogen 41

Biogen Enters into Partnership with Genomics 42

Ewopharma Enters into Distribution Agreement with Biogen 43

Siemens Healthcare Enters into Co-Development Agreement with Biogen 44

Amyris Enters into Agreement with Biogen 45

Biogen Enters into Co-Development Agreement with University of Pennsylvania 46

AC Immune Enters into Partnership with Biogen 47

Rodin Therapeutics Enters into R&D Agreement with Biogen 48

Arsia Therapeutics Enters into Research Agreement with Biogen 49

BioMotiv Expands its Agreement with Biogen 50

Renovo Neural Partners with Biogen 51

Biogen Enters into Agreement with Parkinson's Institute and Clinical Center 52

Biogen's Partner Swedish Orphan Biovitrum To Exercise Its Option for Alprolix 53

Intec Pharma Enters into Research Agreement with Biogen MA 54

Biogen Idec, Fondazione Telethon and Ospedale San Raffaele Enter into Agreement to Develop Gene Therapies for Hemophilia 56

Biogen Idec Enters into Research Agreement with Columbia University Medical Center 57

Swedish Orphan Biovitrum Exercises Option Agreement with Biogen Idec for Elocta 58

Biogen Idec Expands Co-Development Agreement with Swedish Orphan Biovitrum 59

Array BioPharma Enters into Drug Discovery Agreement with Biogen Idec 60

Evotec Enters Into Agreement With Panion For Developing Chronic Pain Treatments 61

White Head Institute And Biogen Idec Enter Into Reasearch Agreement 62

Eisai Expands Co-Development Agreement with Biogen 63

Biogen Idec Enters Into Agreement With UCB To Commercialize Multiple Sclerosis And Hemophilia Therapies 65

Biogen Idec Enters Into Co-Marketing Agreement With Samsung Bioepis To Commercialize Anti-TNF Biosimilar Product Candidates 66

Amicus Therapeutics Enters Into Co-Development Agreement With Biogen Idec 67

Biogen Idec And Isis Pharma Enter Into R&D Agreement To Develop Treatments For Neurological Disorders 68

Biogen Idec Enters Into Agreement With Isis Pharma To Develop Antisense Drugs For Neurological Disorders 69

Biogen Idec Enters Into Agreement With Isis Pharma To Develop Antisense Drug For Myotonic Dystrophy 70

Samsung Forms Joint Venture With Biogen Idec 72

Biogen Idec Amends Co-Development Agreement With Swedish Orphan Biovitrum For rFVIIIFc And rFIXFc Hemophilia Programs 73

Biogen Idec Enters Into Co-Development Agreement With Isis Pharma 74

Biogen Enters into Licensing Agreement with Alkermes 75

Biogen Enters into Licensing Agreement with Bristol-Myers Squibb 76

Biogen Enters into Licensing Agreement with Forward Pharma 77

Biogen Exercises Option for Licensing Agreement with Amunix Operating for Factor IX, XTEN technology 79

Biogen Exercises Option for Licensing Agreement with Ionis Pharma 80

Biogen Enters into Licensing Agreement with RegenxBio 81

Biogen Enters into Licensing Agreement with Applied Genetic Technologies 82

bluebird bio Enters into Licensing Agreement with Biogen 83

Biogen Idec Exercises Option For Licensing Agreement With Amunix Operating For XTENylated Factor VIII 84

Biogen Idec Enters into Licensing Agreement with Sangamo BioSciences for Hemoglobinopathies Therapeutics 85

Sunesis Pharma Enters Into Licensing Agreement With Biogen Idec 86

MAKScientific Enters Into Option For Licensing Agreement With Biogen Idec 87

Biogen Idec Enters Into Licensing Agreement With Myelin Repair Foundation 88

Bioverativ Spin Off from Biogen 89

Rodin Therapeutics to Raise USD17.3 Million in Private Placement of Preferred Stock 90

Applied Genetic Tech Raises USD30 Million in Private Placement of Shares 91

Biogen Raises USD1.5 Billion in Public Offering of 2.9% Notes Due 2020 93

Biogen Raises USD1.75 Billion in Public Offering of 5.2% Notes Due 2045 95

Biogen Raises USD1.75 Billion in Public Offering of 4.05% Notes Due 2025 97

Biogen Raises USD1 Billion in Public Offering of 3.625% Notes Due 2022 99

Brammer Bio Acquires Cambridge Site from Biogen 101

Kiniksa Pharma Acquires Certain Assets Relating to KPL-716 from Biogen 102

Royalty Pharma Acquires Additional Stake In Tecfidera, Oral Multiple Sclerosis Drug, For USD 510 Million 104

DRI Capital Acquires Royalty Rights To Benlysta From Biogen Idec 105

Royalty Pharma Acquires BG-12 And Fumaderm From Fumapharm For USD 761 Million 106

Biogen to Acquire 44.5% Stake in Samsung Bioepis from Samsung BioLogics for USD700 Million 107

Biogen Idec Acquires Convergence Pharma for up to USD650.1 Million 108

Bristol-Myers Rumored To Acquire Biogen Idec 109

Biogen Idec Completes Acquisition Of Remaining Stake In Stromedix, Provider Of Therapies For Fibrosis 110

Takeda Completes Acquisition Of Intellikine For USD 310 Million 112

Biogen Inc, Key Competitors 114

Biogen Inc, Key Employees 115

Biogen Inc, Other Locations 117

Biogen Inc, Subsidiaries 117

Biogen Inc, Joint Venture 121

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@] kenresearch.com
 

Biogen Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

select a license
Single User License
USD 250 INR 17500
Site License
USD 500 INR 35000
Corporate User License
USD 750 INR 52500

NEWSLETTER BY CATEGORY




Testimonials

The report was very informative and gives me an interesting view on the Indian market....

We would like to thank the entire team of Ken Research in showcasing professionalism in research and quick turnaround time. We have had multiple research reports from Ken Research. The deadline communicated for research was duly met. The research reports were covering many aspects in detail. This showcases their endeavor and care for client satisfaction and a strong understanding of the clients’ requirements. Thank you again for your help...

I appreciate their diligence and determination in customizing the research project. The data proves to be valuable and accurate. I would, in future, definitely use their services again...

I would like to thank Ken research team for meeting our report deliverables. The report is very good and we appreciate your well cooperation. ...

The research you conducted was very helpful for us and the integrity of your research approach gave us great confidence in the data. Look forward to collaborating again in future...



Ken Research Private Limited, Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

sales [@] kenresearch.com